BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Simponi (golimumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Simponi (golimumab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07904780-11@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20291111
DTEND;VALUE=DATE:20291112
SUMMARY:Simponi (golimumab): Phase 4 readout est. (NCT07904780)
DESCRIPTION:Simponi (golimumab)\, phase 4.\nStudy: Withdrawal Versus Contin
 ued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile
  Idiopathic Arthritis\nEstimated primary completion: 11 November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/golimumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07904780
URL:https://assetmemo.bio/drug/golimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683026-11@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20320901
DTEND;VALUE=DATE:20320902
SUMMARY:Simponi (golimumab): Phase 2 readout est. (NCT07683026)
DESCRIPTION:Simponi (golimumab)\, phase 2.\nStudy: Platform Trial in Stage 
 1 Diabetes: Comparing Golimumab vs Placebo\nEstimated primary completion: 
 1 September 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gol
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07683026
URL:https://assetmemo.bio/drug/golimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
